Laurus Labs

Laurus Labs delivered a strong FY26 with revenue of ₹6,813 croreCurrent reported value: ₹6,813 crore. No comparable prior figure is available in the source record. (+23Current reported value: 23. No comparable prior figure is available in the source record.% YoY) and EBITDA margin expansion of 670 bps to 26.8%Current reported value: 670 bps to 26.8%. No comparable prior figure is available in the source record., driven by a 38% surge in small molecule CDMO (₹1,896 crCurrent ₹1,896 Cr. Reported change: +38% YoY.ore) and 18% growth in affordable medicines (₹4,733 crore). PAT jumped 148% to ₹889 croreCurrent reported value: 148% to ₹889 crore. No comparable prior figure is available in the source record. as gross margins improved to 60.4% on better mix and raw material softening. Management guided for continued CDMO growth, with capex of ₹3,000 crore over two yearsCurrent reported value: ₹3,000 crore over two years. No comparable prior figure is available in the source record. for capacity expansion (Unit 7, peptide, fermentation). However, geopolitical disruptions could pressure raw material availability and logistics, posing near-term headwinds for the generics business.